ANTX
AN2 Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.05
+3.06%1
Insider buys (3m)
10
Insider sells (3m)
-$331.4K
Net value (3m)
-8.1%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 16, 2026 | Trenor Cameron C. III · officer: Chief Medical Officer | A-Award | 233,333 | $5.36 |
| Sep 16, 2026 | Trenor Cameron C. III · officer: Chief Medical Officer | A-Award | 116,667 | $0.00 |
| Sep 11, 2026 | Readnour Robin Shane · director | Sale | 523 | $6.02 |
| Sep 11, 2026 | Readnour Robin Shane · director | Sale | 585 | $6.02 |
| Sep 8, 2026 | Readnour Robin Shane · director | Sale | 2,877 | $6.07 |
| Sep 8, 2026 | Readnour Robin Shane · director | Sale | 5,294 | $6.02 |
| Sep 8, 2026 | Readnour Robin Shane · director | Sale | 4,725 | $6.02 |
| Sep 8, 2026 | Readnour Robin Shane · director | Sale | 3,223 | $6.07 |
| Sep 4, 2026 | Williams Sarah Joanne · officer: Principal Accounting Officer | Sale | 272 | $5.53 |
| Sep 2, 2026 | FitzPatrick Margaret M · director | Purchase | 2,098 | $5.53 |
| Aug 19, 2026 | Readnour Robin Shane · director | Sale | 18,706 | $6.01 |
| Aug 19, 2026 | Readnour Robin Shane · director | Sale | 16,696 | $6.01 |
| Jul 10, 2026 | Aziz Kabeer · director | A-Award | 2,852 | $0.00 |
| Jul 10, 2026 | Eizen Joshua M · officer: See Remarks | Sale | 5,945 | $4.17 |
| Jul 10, 2026 | Martin Patricia A. · director | A-Award | 766 | $0.00 |
| Jul 10, 2026 | Marks Gilbert Lynn · director | A-Award | 2,789 | $0.00 |
| Jun 2, 2026 | Williams Sarah Joanne · officer: Principal Accounting Officer | Sale | 265 | $4.43 |
| Apr 10, 2026 | Martin Patricia A. · director | A-Award | 1,192 | $0.00 |
| Apr 10, 2026 | Aziz Kabeer · director | A-Award | 3,775 | $0.00 |
| Apr 10, 2026 | Marks Gilbert Lynn · director | A-Award | 3,775 | $0.00 |
| Mar 23, 2026 | Wong Stephanie · director | A-Award | 23,742 | $3.91 |
| Mar 23, 2026 | Zakrzewski Joseph S · director | A-Award | 99,999 | $3.91 |
| Mar 23, 2026 | Zakrzewski Joseph S · director | A-Award | 10,362 | $3.91 |
| Mar 23, 2026 | Zakrzewski Joseph S · director | A-Award | 23,742 | $3.91 |
| Mar 23, 2026 | Eizen Joshua M · officer: See Remarks | A-Award | 92,000 | $3.91 |
| Mar 23, 2026 | Eizen Joshua M · officer: See Remarks | A-Award | 50,150 | $3.91 |
| Mar 23, 2026 | Spigelman Melvin K · director | A-Award | 16,941 | $3.91 |
| Mar 23, 2026 | Spigelman Melvin K · director | A-Award | 10,362 | $3.91 |
| Mar 23, 2026 | Spigelman Melvin K · director | A-Award | 23,742 | $3.91 |
| Mar 23, 2026 | Readnour Robin Shane · director | A-Award | 20,724 | $3.91 |
Institutional positioning
13F filings over the trailing two quarters
New 53Increased 27Reduced 23Sold out 14
| Filer | Action | Shares | Filed |
|---|---|---|---|
| Vivo Capital, LLC | Unchanged | 3,153,640 | Aug 14, 2026 |
| VIVO CAPITAL, LLC | New Position | 3,153,640 | May 20, 2026 |
| Commodore Capital LP | Increased | 2,933,680 | Aug 14, 2026 |
| COMMODORE CAPITAL LP | New Position | 2,333,713 | May 15, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 2,318,692 | Aug 14, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 2,222,502 | May 15, 2026 |
| BlackRock, Inc. | Increased | 1,665,494 | Aug 7, 2026 |
| Spruce Street Capital LP | Unchanged | 1,661,073 | Aug 13, 2026 |
| Spruce Street Capital LP | New Position | 1,661,073 | May 14, 2026 |
| ALMITAS CAPITAL LLC | Unchanged | 1,479,129 | May 15, 2026 |
| Almitas Capital LLC | Reduced | 1,469,129 | Aug 17, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 1,238,705 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 1,011,078 | May 15, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | Unchanged | 1,000,000 | Aug 14, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | New Position | 1,000,000 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 16, 2026